Advertisement
News
Advertisement

Initial results of its REDUCE First-In-Man clinical study presented at "TRenD 2012" transcatheter renal denervation scientific meeting

Mon, 02/20/2012 - 4:45am
The Associated Press

FRANKFURT, Germany--(BUSINESS WIRE)--Feb 20, 2012-- ReCor Medical , an emerging medical device company, announced today that its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation has received the CE mark. PARADISE is designed to treat patients with 'resistant' hypertension ("HTN"), a major risk factor for cardiovascular disease.

The F-I-M clinical data for PARADISE were reported at the "TRenD 2012" transcatheter renal denervation scientific meeting by cardiologist Thomas A. Mabin, M.D., Vergelegen Medi-Clinic, South Africa. The PARADISE data showed that systolic blood pressure was reduced by an average of31 mm Hg in 7 patients at 60-day follow-up.

"PARADISE is designed to offer a minimally invasive ultrasound therapy to resistant hypertension patients to help reduce their blood pressure," said Mano Iyer, CEO, ReCor Medical. "We are extremely pleased with our First-In-Man clinical results as we prepare to launch PARADISE in Europe." "The initial results with PARADISE are impressive," added Professor Marc Sapoval, Hopital Europeen Georges-Pompidou, Paris, who is a member of ReCor Medical's Medical Advisory Board. "This degree of blood pressure reduction has significant health benefits for patients." PARADISE includes a 6 French-compatible catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a rapid and highly efficient renal denervation procedure. The advantage of PARADISE is its ability to uniformly denervate all the way around the arterial wall while simultaneously cooling the endothelium, to help enable a safe, consistent, and fast renal denervation procedure.

About ReCor Medical, Inc.

Founded in 2009, ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology.

ReCor is backed by European and U.S. investors including Sofinnova Partners, one of the largest life science investors in Europe. The Company's PARADISE(TM) technology for renal denervation is CE-marked.

For more information about ReCor Medical, please visit the Company's website at www.recormedical.com.

NOTE: PARADISE(TM) is approved for sale in Europe; it is not approved for sale or investigational use in the United States.

CONTACT: Ronald Trahan Associates Inc.

Ronald Trahan, APR, +1-508-359-4005, x108 President KEYWORD: UNITED STATES EUROPE NORTH AMERICA MASSACHUSETTS GERMANY INDUSTRY KEYWORD: SURGERY HEALTH CARDIOLOGY CLINICAL TRIALS MEDICAL DEVICES SOURCE: ReCor Medical, Inc.

Copyright Business Wire 2012 PUB: 02/20/2012 09:30 AM/DISC: 02/20/2012 09:30 AM http://www.businesswire.com/news/home/20120220005481/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading